Ralph A Tripp

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 55

Top Venues

University of Georgia

Oregon State University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Georgia

United States

Professor and Georgia Research Alliance Chair :: Infectious Diseases

Education History

Oregon State University

United States

PHD

Publications

Jackelyn Murray, David E Martin, Sarah Hosking, Nichole Orr-Burks, Robert J Hogan, Ralph A Tripp
Probenecid Inhibits Influenza A(H5N1) and A(H7N9) Viruses In Vitro and in Mice. Viruses 16 (1) (2024)
Harrison C Bergeron, Jackelyn Crabtree, Tamas Nagy, David E Martin, Ralph A Tripp
Probenecid Inhibits Human Metapneumovirus (HMPV) Replication In Vitro and in BALB/c Mice. Viruses 16 (7) (2024)
Harrison C Bergeron, Jackelyn Crabtree, Tamas Nagy, David E Martin, Ralph A Tripp
Probenecid Inhibits Human Metapneumovirus (HMPV) Replication In Vitro and in BALB/c Mice. Viruses 16 (7) (2024)
Jackelyn Murray, David E Martin, Sarah Hosking, Nichole Orr-Burks, Robert J Hogan, Ralph A Tripp
Probenecid Inhibits Influenza A(H5N1) and A(H7N9) Viruses In Vitro and in Mice. Viruses 16 (1) (2024)
Z Beau Reneer, Harrison C Bergeron, Stephen Reynolds, Elena Thornhill-Wadolowski, Lan Feng, Marcin Bugno, Agnieszka D Truax, Ralph A Tripp
mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge. PloS one 19 (4) (2024)
Z Beau Reneer, Harrison C Bergeron, Stephen Reynolds, Elena Thornhill-Wadolowski, Lan Feng, Marcin Bugno, Agnieszka D Truax, Ralph A Tripp
mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge. PloS one 19 (4) (2024)
Jackelyn Murray, David E Martin, Sarah Hosking, Nichole Orr-Burks, Robert J Hogan, Ralph A Tripp
Probenecid Inhibits Influenza A(H5N1) and A(H7N9) Viruses In Vitro and in Mice. Viruses 16 (1) (2024)
Harrison C Bergeron, Jackelyn Crabtree, Tamas Nagy, David E Martin, Ralph A Tripp
Probenecid Inhibits Human Metapneumovirus (HMPV) Replication In Vitro and in BALB/c Mice. Viruses 16 (7) (2024)
Z Beau Reneer, Harrison C Bergeron, Stephen Reynolds, Elena Thornhill-Wadolowski, Lan Feng, Marcin Bugno, Agnieszka D Truax, Ralph A Tripp
mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge. PloS one 19 (4) (2024)
Z Beau Reneer, Harrison C Bergeron, Stephen Reynolds, Elena Thornhill-Wadolowski, Lan Feng, Marcin Bugno, Agnieszka D Truax, Ralph A Tripp
mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge. PloS one 19 (4) (2024)
Jackelyn Murray, David E Martin, Sarah Hosking, Nichole Orr-Burks, Robert J Hogan, Ralph A Tripp
Probenecid Inhibits Influenza A(H5N1) and A(H7N9) Viruses In Vitro and in Mice. Viruses 16 (1) (2024)
Ralph A Tripp, David E Martin
Antiviral agents and therapeutics against respiratory viruses. Expert opinion on investigational drugs (2024)
David E Martin, Neelam Pandey, Purvi Chavda, Gurpreet Singh, Rakesh Sutariya, Frederic Sancilio, Ralph A Tripp
Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19. Viruses 15 (7) (2023)
Ralph A Tripp
Understanding immunity to influenza: implications for future vaccine development. Expert review of vaccines (2023)
Harrison C Bergeron, Matthew R Hansen, Ralph A Tripp
Interferons-Implications in the Immune Response to Respiratory Viruses. Microorganisms 11 (9) (2023)
Harrison C Bergeron, Jackelyn Murray, Aakash Arora, Ana M Nuñez Castrejon, Rebecca M DuBois, Larry J Anderson, Lawrence M Kauvar, Ralph A Tripp
Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein. Viruses 15 (5) (2023)
Jackelyn Murray, David E Martin, Fred D Sancilio, Ralph A Tripp
Antiviral Activity of Probenecid and Oseltamivir on Influenza Virus Replication. Viruses 15 (12) (2023)
Jackelyn Murray, David E Martin, Fred D Sancilio, Ralph A Tripp
Antiviral Activity of Probenecid and Oseltamivir on Influenza Virus Replication. Viruses 15 (12) (2023)
Ralph A Tripp, David E Martin
Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19. Viruses 15 (11) (2023)
Jackelyn Murray, David E Martin, Fred D Sancilio, Ralph A Tripp
Antiviral Activity of Probenecid and Oseltamivir on Influenza Virus Replication. Viruses 15 (12) (2023)
Ralph A Tripp, David E Martin
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication. Viruses 14 (3) (2022)
Thomas J Powell, Andrea Jacobs, Jie Tang, Edwin Cardenas, Naveen Palath, Jennifer Daniels, James G Boyd, Harrison C Bergeron, Patricia A Jorquera, Ralph A Tripp
Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge. Vaccines 10 (12) (2022)
Les Jones, Hemant K Naikare, Yung-Yi C Mosley, Ralph A Tripp
Isothermal amplification using sequence-specific fluorescence detection of SARS coronavirus 2 and variants in nasal swabs. BioTechniques 72 (6) (2022)
Harrison C Bergeron, Ralph A Tripp
RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein. Viruses 14 (11) (2022)
Jackelyn Murray, Harrison C Bergeron, Les P Jones, Zachary Beau Reener, David E Martin, Fred D Sancilio, Ralph A Tripp
Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication. Viruses 14 (5) (2022)
Thomas J Powell, Andrea Jacobs, Jie Tang, Edwin Cardenas, Naveen Palath, Jennifer Daniels, James G Boyd, Harrison C Bergeron, Patricia A Jorquera, Ralph A Tripp
Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge. Vaccines 10 (12) (2022)
Thomas J Powell, Andrea Jacobs, Jie Tang, Edwin Cardenas, Naveen Palath, Jennifer Daniels, James G Boyd, Harrison C Bergeron, Patricia A Jorquera, Ralph A Tripp
Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge. Vaccines 10 (12) (2022)
Thomas J Powell, Andrea Jacobs, Jie Tang, Edwin Cardenas, Naveen Palath, Jennifer Daniels, James G Boyd, Harrison C Bergeron, Patricia A Jorquera, Ralph A Tripp
Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge. Vaccines 10 (12) (2022)
Harrison C Bergeron, Zachary Beau Reneer, Aakash Arora, Stephen Reynolds, Tamas Nagy, Ralph A Tripp
Influenza B Virus (IBV) Immune-Mediated Disease in C57BL/6 Mice. Vaccines 10 (9) (2022)
Ralph A Tripp
Advances in Vaccine Development. Vaccines 9 (9) (2021)
Nichole Orr-Burks, Jackelyn Murray, Kyle V Todd, Abhijeet A Bakre, Ralph A Tripp
G-Protein-Coupled Receptor and Ion Channel Genes Used by Influenza Virus for Replication. Journal of virology 95 (9) (2021)
Nichole Orr-Burks, Jackelyn Murray, Kyle V Todd, Abhijeet Bakre, Ralph A Tripp
Drug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro. PloS one 16 (10) (2021)
Harrison C Bergeron, Ralph A Tripp
Immunopathology of RSV: An Updated Review. Viruses 13 (12) (2021)
Les Jones, Abhijeet Bakre, Hemant Naikare, Ravindra Kolhe, Susan Sanchez, Yung-Yi C Mosley, Ralph A Tripp
Isothermal amplification and fluorescent detection of SARS-CoV-2 and SARS-CoV-2 variant virus in nasopharyngeal swabs. PloS one 16 (9) (2021)
Harrison C Bergeron, Ralph A Tripp
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). Expert opinion on investigational drugs 31 (1) (2021)
Ralph A Tripp, John Stambas
Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins. Viruses 13 (4) (2021)
Harrison C Bergeron, Ralph A Tripp
Emerging small and large molecule therapeutics for respiratory syncytial virus. Expert opinion on investigational drugs 29 (3) (2020)
John Stambas, Chunni Lu, Ralph A Tripp
Innate and adaptive immune responses in respiratory virus infection: implications for the clinic. Expert review of respiratory medicine 14 (11) (2020)
Kyle V Todd, Ralph A Tripp
Exosome-mediated human norovirus infection. PloS one 15 (8) (2020)
Seyhan Boyoglu-Barnum, Ralph A Tripp
Up-to-date role of biologics in the management of respiratory syncytial virus. Expert opinion on biological therapy 20 (9) (2020)
Ralph A Tripp, Paul S McNamara
Pathobiology of Respiratory Syncytial Virus (RSV). Vaccines 8 (3) (2020)
Kyle V Todd, Ralph A Tripp
Vero Cells as a Mammalian Cell Substrate for Human Norovirus. Viruses 12 (4) (2020)
Kelsey Briggs, Leyi Wang, Kaito Nagashima, James Zengel, Ralph A Tripp, Biao He
Regulation of Mumps Virus Replication and Transcription by Kinase RPS6KB1. Journal of virology 94 (12) (2020)
Ralph A Tripp, Ultan F Power
Original Antigenic Sin and Respiratory Syncytial Virus Vaccines. Vaccines 7 (3) (2019)
Hua Wu, Zhiqiang Fan, Michelle Brandsrud, Qinggang Meng, Molly Bobbitt, Misha Regouski, Rusty Stott, Alexis Sweat, Jackelyn Crabtree, Robert J Hogan, Ralph A Tripp, Zhongde Wang, Irina A Polejaeva, Eddie J Sullivan
Generation of H7N9-specific human polyclonal antibodies from a transchromosomic goat (caprine) system. Scientific reports 9 (1) (2019)
Patricia A Jorquera, Cynthia Mathew, Jennifer Pickens, Colin Williams, Jasmina M Luczo, Sharon Tamir, Reena Ghildyal, Ralph A Tripp
Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro. Journal of virology 93 (4) (2019)
Kyle V Todd, Ralph A Tripp
Human Norovirus: Experimental Models of Infection. Viruses 11 (2) (2019)
Yael Bar-Peled, Darren Diaz, Alma Pena-Briseno, Jackelyn Murray, Jiachen Huang, Ralph A Tripp, Jarrod J Mousa
A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo. Journal of virology 93 (19) (2019)
Ralph A Tripp, Ultan F Power, Peter J M Openshaw, Lawrence M Kauvar
Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. Journal of virology 92 (3) (2018)
Jennifer A Pickens, Ralph A Tripp
Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses. Viruses 10 (1) (2018)
Adam Vigil, Angeles Estélles, Lawrence M Kauvar, Scott K Johnson, Ralph A Tripp, Michael Wittekind
Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses. Antimicrobial agents and chemotherapy 62 (5) (2018)
Abhijeet A Bakre, Byoung-Shik Shim, Ralph A Tripp
MicroRNA-134 regulates poliovirus replication by IRES targeting. Scientific reports 7 (1) (2017)
Alaina J Mooney, Jon D Gabbard, Zhuo Li, Daniel A Dlugolenski, Scott K Johnson, Ralph A Tripp, Biao He, Stephen Mark Tompkins
Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge. Journal of virology 91 (23) (2017)
Jackelyn Murray, Kyle V Todd, Abhijeet A Bakre, Nichole Orr-Burks, Les Jones, Weilin Wu, Ralph A Tripp
A universal mammalian vaccine cell line substrate. PloS one 12 (11) (2017)
Patricia A Jorquera, Ralph A Tripp
Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert review of respiratory medicine 11 (8) (2017)

Ralph A Tripp.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ralph A Tripp